Biomea Fusion has dosed the first participant in a new OPAL study arm testing icovamenib in combination with semaglutide. The milestone moves a preclinically pr

Biomea Fusion has dosed the first participant in a new OPAL study arm testing icovamenib in combination with semaglutide. The milestone moves a preclinically promising pairing into human evaluation after earlier reported 12-week HbA1c improvements.